The Mitsubishi Tanabe Pharma Group engages Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) across Europe.
In accordance with the EFPIA Code of Transfers of Value from Pharmaceutical Companies 2019, details of Transfers of Value made to HCPs and HCOs in Europe by the Mitsubishi Tanabe Pharma Group can be found below.
The methodology applied in preparing and collating this data is available here in English*, French* and German*. test
If you are a Healthcare Professional and have any questions regarding the figures disclosed, please contact:
Finance@mt-pharma-eu.com.
2024 Transfers of Value
AUSTRIA |
| Research & Development | EUR 57,285.61 |
| Non-Research & Development | EUR 60,284.52 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
BELGIUM |
| Research & Development | EUR 29,614.54 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 39,375.00 |
| Full details here |
BULGARIA |
| Research & Development | BGN 0.00 |
| Non-Research & Development | BGN 0.00 |
| Patient Organisation & Advisory Groups | BGN 0.00 |
| Full details here |
CROATIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
CYPRUS |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
CZECH REPUBLIC |
| Research & Development | CZK 827,582.29 |
| Non-Research & Development | CZK 0.00 |
| Patient Organisation & Advisory Groups | CZK 0.00 |
| Full details here |
DENMARK |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
ESTONIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
FINLAND |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
FRANCE |
| Research & Development | EUR 40,722.62 |
| Non-Research & Development | EUR 375.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
GERMANY |
| Research & Development | EUR 269,651.95 |
| Non-Research & Development | EUR 325,775.13 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
GREECE |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
HUNGARY |
| Research & Development | HUF 0.00 |
| Non-Research & Development | HUF 0.00 |
| Patient Organisation & Advisory Groups | HUF 0.00 |
| Full details here |
IRELAND |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
ITALY |
| Research & Development | EUR 256,189.92 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
LATVIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
LITHUANIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
MALTA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
THE NETHERLANDS |
| Research & Development | EUR 14,582.66 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
NORWAY |
| Research & Development | NOK 51,826.25 |
| Non-Research & Development | NOK 0.00 |
| Patient Organisation & Advisory Groups | NOK 0.00 |
| Full details here |
POLAND |
| Research & Development | PLN 584,392.11 |
| Non-Research & Development | PLN 0.00 |
| Patient Organisation & Advisory Groups | PLN 0.00 |
| Full details here |
PORTUGAL |
| Research & Development | EUR 7,020.21 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
ROMANIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
RUSSIA |
| Research & Development | RUB 6,946,955.99 |
| Non-Research & Development | RUB 0.00 |
| Patient Organisation & Advisory Groups | RUB 0.00 |
| Full details here |
SERBIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
SLOVAKIA |
| Research & Development | EUR 35,210.83 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
SLOVENIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
SPAIN |
| Research & Development | EUR 180,640.03 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
SWEDEN |
| Research & Development | SEK 66,058.25 |
| Non-Research & Development | SEK 0.00 |
| Patient Organisation & Advisory Groups | SEK 151,801.00 |
| Full details here |
SWITZERLAND |
| Research & Development | CHF 50,300.11 |
| Non-Research & Development | CHF 84,350.00 |
| Patient Organisation & Advisory Groups | CHF 0.00 |
| Full details here |
TURKEY |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
UKRAINE |
| Research & Development | EUR 62,547.38 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
* The Mitsubishi Tanabe Pharma Group has established legal entities in the United Kingdom, Germany and Switzerland and therefore disclosure is made according to local requirements for these countries
